Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12001 - 12025 of 12647 in total
Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).
Investigational
Matched Description: … Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 …
GSK-239512 is under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.).
Investigational
Matched Description: … under investigation in clinical trial NCT00474513 (An Imaging Study to Investigate the Distribution of
Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).
Investigational
Matched Description: … Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 …
2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Investigational
Matched Description: … 2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients …
Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)).
Investigational
Matched Description: … Tefinostat is under investigation in clinical trial NCT02759601 (Dose Escalation Trial of Tefinostat …
Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With …
Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).
Investigational
Matched Description: … formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of
Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.
Investigational
Matched Description: … Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds …
Apinocaltamide is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients).
Investigational
Matched Description: … Apinocaltamide is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of
Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
Investigational
Matched Description: … Abelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab …
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Matched Description: … U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and …
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Dalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.
Investigational
Matched Description: … It is being investigated for the treatment of hemophilia B.[A259058] …
SPL23-2 is an antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of cystic fibrosis.
Investigational
Matched Description: … antisense oligonucleotide (ASO) targeting the W1282X nonsense mutation associated with a severe form of
Xeligekimab is under investigation in clinical trial NCT06028490 (A Study of Il4rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.).
Investigational
Matched Description: … Xeligekimab is under investigation in clinical trial NCT06028490 (A Study of Il4rα Monoclonal Antibody …
Rulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).
Investigational
Matched Description: … Rulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab …
Veligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma).
Investigational
Matched Description: … Veligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients …
Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection).
Investigational
Matched Description: … Rifasutenizol is under investigation in clinical trial NCT05857163 (Efficacy and Safety of Rifasutenizol …
Fepixnebart is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis).
Investigational
Matched Description: … is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of
A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.
Experimental
Illicit
KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
Investigational
Matched Description: … KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of
IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.
Investigational
Matched Description: … IR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. …
AAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human AIPL1 gene. Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in AIPL1 gene.
Investigational
Matched Description: … Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due …
Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer).
Investigational
Matched Description: … Vepdegestrant is under investigation in clinical trial NCT05909397 (A Study of ARV-471 (PF-07850327) …
Displaying drugs 12001 - 12025 of 12647 in total